Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

RESEARCH ARTICLE

Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy?

Baljinder Singh, Vikas Prasad, Christiane Schuchardt, Harshad Kulkarni, Richard P Baum

Citation Information : Singh B, Prasad V, Schuchardt C, Kulkarni H, Baum RP. Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy?. J Postgrad Med Edu Res 2013; 47 (1):7-13.

DOI: 10.5005/jp-journals-10028-1050

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

Introduction

Neuroendocrine neoplasms express somatostatin receptors, enabling the use of somatostatin analogs for molecular imaging, when labeled with the positron-emitter 68Ga for receptor positron emission tomography/computed tomography (PET/CT), and targeted radionuclide therapy, when labeled with beta-emitters, e.g. 90Y and 177Lu.

Aim

To investigate if 68Ga-DOTATATE PET-derived standardized uptake values (SUV) correlate with the dose delivered to the liver lesions following 177Lu-DOTATATE radionuclide therapy in patients with neuroendocrine neoplasms.

Materials and methods

Twelve adult (8M: 4F; mean age: 55.9 ± 14.5 years; range: 23-78 years) patients with documented neuroendocrine tumor (NET) disease and liver metastases were enrolled in the study. Ten patients were subjected to 68Ga-DOTATATE and one patient each underwent 68Ga-DOTATOC and 68Ga-DOTANOC diagnostic PET/CT imaging. Subsequently, on the basis of positive PET/CT scan findings for the metastatic NET disease, all these patients were subjected to peptide receptor radionuclide therapy (PRRNT) with 177Lu-DOTATATE. The reconstructed PET/CT data was used to calculate the SUVs on the identifiable liver lesions. The scintigraphic data acquired (anterior and posterior whole body images) following therapeutic doses of 177Lu-DOTATATE were subjected to the quantitative analysis (HERMES workstation and OLINDA/EXM software) to calculate the dose delivered to the hepatic lesions.

Results

The initial results of this preliminary study indicate poor correlation between SUV and the tumor dose and the linear regression analysis provided R2 values which explained only a small fraction of the total variance.

Conclusion

The SUVs derived from 68Ga-DOTA-peptide PET/CT images should be used with caution for the prediction of tumor dose on 177Lu-DOTA-peptide therapy as there are large intra- and interpatient variability. Further studies with large numbers of patients are warranted to establish such a correlation between SUV, tumor dose and the response assessment.

How to cite this article

Singh B, Prasad V, Schuchardt C, Kulkarni H, Baum RP. Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy? J Postgrad Med Edu Res 2013;47(1):7-13.


PDF Share
  1. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228
  2. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097-104.
  3. PET/CT in neuroendocrine tumors: Evaluation of receptor status and metabolism. PET Clinics 2008;2:351-75.
  4. 68Ga-DOTA-NOC a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724
  5. DOTA-NOC: A high affinity ligand for somatostatin receptors subtypes 2 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47.
  6. MIRD Pamphlet 16: Techniques for quantitative radiopharmaceuticals biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S.
  7. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled analogs. J Nucl Med 2005;46:92S.
  8. High radiotherapeutic efficacy of 177Lu-DOTA-Y3-octreotate in rat tumor model. J Nucl Med 1999;40(S):223
  9. Treatment of patients with gastroentero-pancreatic (GEP) tumors with the novel radiolabelled somtaostatin analogue [177Lu-DOATA0, Tyr3] octreotate. Eur J Nucl Med 2003;30:417
  10. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTA-TATE and 177Lu-DOTA-NOC. Cancer Biotherapy and Radiopharmaceuticals 2007;22:406-16.
  11. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal and hepatocyte lysosomes. Cancer Res 1997;57:659-71.
  12. 177Lu-DOTA0,Try3: Comparison with [111In DTPTA0 octreotide in patients. Eur J Nucl Med 2001; 28:319-25.
  13. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 2006;47:1467-75.
  14. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA (0), Try (3)-octreotide and 177Lu-DOTA0, Try3-octreotate. J Nucl Med 2005;46(S)1:83S-91S.
  15. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23: 2754-62.
  16. J Clin Oncol 2004;22:2724-29.
  17. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and therapeutic use. Eur J Nucl Med 2000;27:273-82.
  18. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103:16436-41.
  19. Up-regulation of somatostatic receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0, Try3]octreotide therapy. Q J Nucl Med Mol Imaging 2007;51:324-33.
  20. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med 2012;37(6):e141-e47.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.